Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant ...
Author Archive - Laiba Immad
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results – Updated
Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT...
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the treatment of extensive-stage small cell lung cancer...
The Ensign Group, Inc. (ENSG) Expands with Acquisition of Three Skilled Nursing Facilities in Idaho and California
Effective June 1, the firm took over operations at Ironwood Rehabilitation and Care Center (80 beds) and Lakeside Rehabilitation and Care Center (100 beds), both in Coeur d’...
Align Technology, Inc. (ALGN) Awards $300K in Global Research Grants
The 2025 grants, announced June 2, support innovative dental and orthodontic research across the Americas, Europe, and Asia Pacific, with recipients including the University of...
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer
Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective...
Corcept Therapeutics Incorporated (CORT)’s Reports Promising Phase 3 Results for Ovarian Cancer Drug
Corcept Therapeutics Incorporated (NASDAQ:CORT) is making headlines after its Phase 3 ROSELLA trial showed relacorilant, combined with nab-paclitaxel, reduced disease progression...
Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy...
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results
Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35%
A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc.
BeOne Medicines Ltd. (ONC)’s Combo Drug Shows Strong CLL Response
BeOne Medicines Ltd.
Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial
Xilio Therapeutics, Inc.
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis
Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD).
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial
Perspective Therapeutics, Inc.
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial
CERo Therapeutics Holdings, Inc.
Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment.
Teva Pharmaceutical Industries Limited (TEVA) Study Finds Gaps in Tardive Dyskinesia Care at Long-Term Facilities
A new study from Teva Pharmaceutical Industries Limited (NYSE:TEVA) has uncovered alarming gaps in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long...
Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced it will present 14 new abstracts, including four oral presentations, at SLEEP 2025, highlighting significant advances for LUMRYZ...
Concord Medical Services Holdings Limited (CCM)’s Subsidiary Debuts Nation’s First Proton Therapy LLM
Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services Holdings Limited (NYSE:CCM), has announced a major breakthrough in cancer care with the launch of ...
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy
Beam Therapeutics Inc. (NASDAQ:BEAM) has secured U.S.
Health Net and Centene Corporation (CNC) Commit Over $7.2 Million to Boost Healthcare Access Through Mobile Clinics in California
Health Net and the Centene Corporation (NYSE:CNC)'s philanthropic arm, Centene Foundation, have announced a major $7.2 million investment to expand healthcare access for underserved...
Morgan Stanley Lifts Performance Food Group Company (PFGC) Stock Target to $93
Morgan Stanley has raised its price target for Performance Food Group Company (NYSE:PFGC) to $93, up from $92, while maintaining an Equalweight rating, following the company’...
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor...
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System
Cytek Biosciences, Inc.
Atlantic International Corp. (ATLN) Launches AI-Powered Workforce Intelligence Platform via Lyneer
Atlantic International Corp.
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc.
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools...
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc.
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
Revelation Biosciences, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the innovative Gibson SOLA system into its laboratories.
